On-demand Therapy for Hereditary Angioedema

被引：3
|
作者：
Bernstein, Jonathan A. [1 ]
机构：
[1] Univ Cincinnati, Allergy Sect, Div Immunol, Dept Internal Med,Coll Med, Cincinnati, OH 45267 USA
来源：
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA | 2013年 / 33卷 / 04期
关键词：
Hereditary angioedema; On-demand therapies; Berinert; Ecallantide; Icatibant; Ruconest; Guidelines; RECOMBINANT HUMAN C1-INHIBITOR; C1 INHIBITOR CONCENTRATE; ACUTE ATTACKS; RECEPTOR ANTAGONIST; CONESTAT ALPHA; MANAGEMENT; ECALLANTIDE; DEFICIENCY; ICATIBANT; EFFICACY;
D O I：
10.1016/j.iac.2013.07.004
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Consensus guidelines on hereditary angioedema (HAE) recommend that all patients have access to on-demand treatment of acute attacks. A recent patientcentric guideline recommended that at least 2 on-demand therapies be available because patients often have heterogeneous responses to different medications. Self-administration of therapeutic agents, or administration under supervision by a health care provider in the home setting, is the preferred treatment approach. Future studies are needed to show the benefits of acute on-demand therapies at improving quality of life and reducing morbidity and mortality in patients with HAE.
引用
收藏
页码：487 / +
页数：10
相关论文
共 50 条
  • [31] Correction: The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks
    Stephen D. Betschel
    Teresa Caballero
    Douglas H. Jones
    Hilary J. Longhurst
    Michael Manning
    Sally van Kooten
    Markus Heckmann
    Sherry Danese
    Ledia Goga
    Autumn Ford Burnette
    Allergy, Asthma & Clinical Immunology, 21 (1)
  • [32] Patients delay treating hereditary angioedema (HAE) attacks with currently available, injectable, on-demand therapies
    Valerieva, A.
    Van Kooten, S.
    Heckmann, M.
    Danese, S.
    Goga, L.
    Longhurst, H.
    ALLERGY, 2023, 78
  • [33] PATIENT-REPORTED ANXIETY IMPACTS UTILIZATION OF INJECTABLE ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS
    Radojicicl, C.
    Burnette, A.
    VanKooten, S.
    Malloy, N.
    Heckmann, M.
    Longhurst, H.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S29 - S29
  • [34] Berotralstat Reduces Use of On-demand Medication in Hereditary Angioedema (HAE) Patients Previously Treated with Prophylactic Therapies
    Gower, Richard
    Busse, Paula
    Best, Jessica
    Murray, Sharon
    Iocca, Heather
    Kinaciyan, Tamar
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB146 - AB146
  • [35] HEREDITARY ANGIOEDEMA AND HEPARIN THERAPY
    COLMAN, RW
    ANNALS OF INTERNAL MEDICINE, 1976, 85 (03) : 399 - 399
  • [36] METHYLTESTOSTERONE THERAPY IN HEREDITARY ANGIOEDEMA
    SHEFFER, AL
    FEARON, DT
    AUSTEN, KF
    ANNALS OF INTERNAL MEDICINE, 1977, 86 (03) : 306 - 308
  • [37] Hereditary angioedema: Optimal therapy
    Sheffer, Albert L.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (04) : 756 - 757
  • [38] New Hereditary Angioedema Therapy
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (05): : 416 - 416
  • [39] Prophylactic Therapy for Hereditary Angioedema
    Longhurst, Hilary
    Zinser, Emily
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2017, 37 (03) : 557 - +
  • [40] INDIRECT TREATMENT COMPARISON OF ORAL SEBETRALSTAT AND INTRAVENOUS RHC1-INH AS ON-DEMAND TREATMENTS FOR HEREDITARY ANGIOEDEMA
    Wang, A.
    Li, H.
    Magerl, M.
    Craig, T.
    Manning, M.
    Hummel, N.
    Audhya, P.
    Bernstein, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S28 - S29
12345